News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–46
Matches
46
Sources here
7
Companies here
1
Search results Stored financial headlines

Active search

46 matching headlines

Ticker or company: TNXPMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Deals and strategy Main company 🇺🇸 United States

Tonix Pharmaceuticals Holding Corp (TNXP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividends and stock splits for Tonix Pharmaceuticals Holding Corp (TNXP). It notes that the company has not distributed any dividends in the past five years but has undergone several stock mergers with various ratios in 2023, 2024, …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Tonix Pharmaceuticals Holding Corp. Revenue Breakdown – NASDAQ:TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) generated $13.11 million USD in revenue last year, primarily from its Therapeutics segment. This represents an increase from $10.09 million USD in the previous year. The United States was the company's largest contributor to revenue.

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Tonix Pharmaceuticals Holding Corp (TNXP) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Tonix Pharmaceuticals Holding Corp (TNXP), noting its robust financial status and low operating efficiency. The company's financial score is 7.77, ranking 101 out of 155 in the Pharmaceuticals industry, with recent quarterly revenue increasing by 183.16% …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Tonix Pharmaceuticals Holding Corp (TNXP) Institutional Confidence

The article details the institutional confidence score for Tonix Pharmaceuticals Holding Corp (TNXP), which stands at 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 32.65%, showing a 27.35% quarter-over-quarter increase. Steven Cohen is identified as …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Balance sheet Main company 🇺🇸 United States

Total debt per share of Tonix Pharmaceuticals Holding Corp. – GETTEX:TPM0

The article focuses on the "Total debt per share" of Tonix Pharmaceuticals Holding Corp. (GETTEX:TPM0) as listed on TradingView. It appears to be a financial data page rather than a detailed news article. The content provides navigational links and information about TradingView's platform, market …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Balance sheet Main company 🇺🇸 United States

Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy

Tonix Pharmaceuticals has released an investor deck detailing the launch strategy for its fibromyalgia drug, TONMYA. The company reported first-quarter 2026 net sales of USD 3.7 million, with total launch-to-date sales reaching USD 5.1 million by March 31, 2026. Tonix also highlighted its strong …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Tonix Pharmaceuticals (TNXP) Investor presentation Summary

Tonix Pharmaceuticals has launched Tonmya, a sublingual tablet for fibromyalgia, which has achieved $5.1 million in net sales and secured broad commercial and government insurance coverage. The company has a strong cash position of $185.5 million and an extensive pipeline of drug candidates for …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Regulatory and legal Main company 🇺🇸 United States

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Tonix Pharmaceuticals announced the publication of research in the Journal of Virology that identified new animal models for investigating mpox pathogenesis and demonstrated significant differences in virulence between mpox clades. The study found that the 2022 outbreak strain (clade IIb) is 100 to 100,000-fold …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Tonix Paper Introduces Three New Mouse Models for Mpox Vaccine Research

Tonix Pharmaceuticals announced that the Journal of Virology published its research on new mpox animal models, revealing that the 2022 clade IIb strain is 100 to 100,000-fold less virulent than the 2003 clade IIa strain. The study expands existing mouse models and introduces three …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Guidance Main company 🇺🇸 United States

Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones

This article analyzes Tonix Pharmaceuticals Holding Corp. (TNXP), highlighting a mid-channel oscillation pattern and a weak long-term outlook despite positive sentiment. It details distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for various risk profiles. The analysis …

TNXP main company
Sharemaestro market context Price below Trend Line 52 weeks -66.5% · Next-week setup negative 42.8% TNXP stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context